Drug Trial Radar · NCT05465954
Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
53
Actual
Start
Jan 24, 2023
Primary completion
Sep 2, 2026
Study completion Sep 2, 2031
Sponsor
- Lead sponsor
- Mayo ClinicAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- NeoImmuneTech; Merck Sharp & Dohme LLC; National Cancer Institute (NCI)
- First posted
- Jul 20, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial tests the safety and side effects of efineptakin alfa and pembrolizumab in treating patients with glioblastoma that has come back (recurrent). Efineptakin alfa is an immunotherapy drug that works by helping the immune system fight tumor cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving efineptakin alfa and pembrolizumab may kill more tumor cells in patients with recurrent glioblastoma.
Conditions
- High Grade Astrocytic Tumor
- Recurrent Glioblastoma, IDH-Wildtype
- Recurrent Gliosarcoma
Interventions
Biospecimen CollectionProcedure
Correlative studies
Efineptakin alfaBiological
Given IM
PembrolizumabBiological
Given IV
BiopsyProcedure
Undergo tumor biopsy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival rateTime frame: Up to 9 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mayo Clinic
Rochester, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.